- Home
- VYNE vs QNCX Comparison
VYNE vs QNCX Comparison
Compare VYNE & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | QNCX |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 19.9M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VYNE | QNCX |
|---|---|---|
| Price | $0.65 | $18.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 117.5K | ★ 449.0K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.08 |
| 52 Week High | $1.72 | $4.55 |
Technical Indicators
Market Signals| Indicator | VYNE | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 98.50 |
| Support Level | $0.62 | $0.77 |
| Resistance Level | $0.69 | N/A |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | 0.00 | 1.08 |
| Stochastic Oscillator | 60.45 | 92.46 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.